[{"Assets_0_Q2_USD":201819000.0,"CommonStockSharesOutstanding_0_Q2_shares":30965296.0,"NetCashProvidedByUsedInOperatingActivities_2_Q2_USD":-43705000.0,"NetIncomeLoss_1_Q2_USD":-31218000.0,"NetIncomeLoss_2_Q2_USD":-61447000.0,"StockholdersEquity_0_Q2_USD":174203000.0,"RevenueFromContractWithCustomerExcludingAssessedTax_1_Q2_USD":3676000.0,"RevenueFromContractWithCustomerExcludingAssessedTax_2_Q2_USD":4794000.0,"Ticker":"ACRS","CIK":"1557746","name":"ACLARIS THERAPEUTICS, INC.","OfficialName":"Aclaris Therapeutics Inc. Common Stock","form":"10-Q","period":"20180630","fy":"2018.0","fp":"Q2","qtrs":"0","uom":"USD","footnote":"nan","Market Cap":"1075670582.0","Country":"United States","Sector":"Health Care","Industry":"Biotechnology: Commercial Physical & Biological Resarch","Market":"NASDAQ","SP500":"nan","filed":"20180803"}]